Skip to content
MedsAcross

Medicine

Xhance 93 mcg nasal spray

Fluticasone propionate · Nasal · Paratek Pharmaceuticals
Available on requestPrescription onlyUS FDA

Xhance 93 mcg nasal spray is a prescription medicine containing Fluticasone propionate for nasal use, marketed by Paratek Pharmaceuticals, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.

Availability

Available on request

Export supply from India to licensed buyers

Typical lead time

On request

Counted from payment and complete documents

Shipping

Ambient

Store at room temperature (between 15°C and 25°C, 59°F and 77°F), excursions…

Key facts

Active ingredient (INN)
Fluticasone propionate
Brand
Xhance
Strength
93 mcg
Dosage form
Nasal spray
Route
Nasal
Packs
1 bottle
Marketing authorisation holder
Paratek Pharmaceuticals
Manufacturers
Paratek PharmaceuticalsOptiNose
Origin register
US FDA, United States
Storage
Store at room temperature (between 15°C and 25°C, 59°F and 77°F), excursions permitted from 15°C to 30°C (59°F to 86°F).
Cold chain
Not required on record
Prescription status
Prescription only
Controlled substance
Not recorded as controlled
HS code (indicative)
3004.32Indicative only. Your customs broker confirms the final tariff code.
Marketing category
marketed
Marketed since
3 October 2017
Identifiers
RxCUI 1946583, 1946589DailyMed set ID 44fcea33-8cfa-3a5c-e063-6394a90aafb2, c79bbb9f-e483-4093-8c92-ea978e7bf278NDC 71715-003, 71143-375Application NDA209022

Record updated 12 November 2026

Documents available

Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.

No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.

Packs

PackCodeLabelerMarketed since
1 bottle in 1 carton / 120 spray, metered in 1 bottle71715-003-31Paratek Pharmaceuticals12 January 2026
1 bottle in 1 carton / 28 spray, metered in 1 bottle71715-003-32Paratek Pharmaceuticals12 January 2026
1 bottle in 1 carton / 120 spray, metered in 1 bottle71143-375-01OptiNose3 October 2017

Status by register

Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.

RegisterStatusSource
US FDAListed, marketedSource record for this pageChecked 12 November 2026
US FDAFirst approved 14 December 1990Drugs@FDA
EU (EMA)Not recorded—
India (CDSCO)Not yet confirmed against CDSCO approval lists—
United StatesRegisteredUS FDA (NDC directory, openFDA)Checked 12 November 2026

Import route

Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.

Import guides are available for 25 countries. Pick one to see its route summary.

BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides

Other strengths and forms of Fluticasone propionate

Clinical summary

Fluticasone propionate is a corticosteroid indicated for the maintenance treatment of asthma as prophylactic therapy in patients aged 4 years and older, among other approved uses. MedsAcross supplies Fluticasone propionate for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.

Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review

Read about Fluticasone propionate

For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.

Data sources

Need Xhance 93 mcg nasal spray for your hospital or patient?

Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.